Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

This Healthcare Stock Disappointed Investors. Here's Why It's Still a Buy.

TheMotleyFool

0 0

This Healthcare Stock Disappointed Investors. Here's Why It's Still a Buy.: https://g.foolcdn.com/editorial/images/708360/gettyimages-1203992576.jpg

AbbVie (NYSE: ABBV) shares have been one of the bright spots in the stock market this year. They're outperforming the S&P 500 index. But the stock has lost a bit of ground since AbbVie's third-quarter earnings report in late October.

The pharmaceutical company noted a slowdown in one of its key businesses -- aesthetics. And its blockbuster immunology drug Humira continued to see sales drop internationally due to biosimilar competition -- and biosimilars will hit the market in the U.S. next year.

All of this may sound grim, but there are positive elements to AbbVie's story that outweigh the negative news, and they're why I still view the stock as a buy.

Source Fool.com

Like: 0

ABBV

Share